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The mechanisms leading to the complex clinico-patholo-
logical picture in Hodgkin's Disease (HD) are poorly under-
stood. In particular, the intimate nature and meaning of
immunological abnormalities extensively reported in this
disease, and the affiliation to a definite cellular lineage of
Hodgkin (H) and Reed-Sternberg (RS) cells, are still a
matter of debate (Hsu et al., 1985; Stein et al., 1985;
Romagnani et al., 1985; Kamesaki et al., 1986). These latter
cells, which are generally considered the malignant prolifer-
ating clone, although rather scanty within the involved
tissues in most cases, seem to play a crucial role in the
disease through a negative influence on the lymphoid
environment. This eventually leads to the well known, yet
unexplained, derangement of the immune system (Frydecka,
1985; Romagnani et al., 1985).
It has been recently demonstrated that a soluble form of
interleukin-2 receptors (sIL-2R), which retains the ability to
bind IL-2, can be released by activated lymphoid cells
(Rubin et al., 1985). High levels of sIL-2R have also been
found in the serum of hairy cell leukaemia (HCL) (Steis et
al., 1986; Chilosi et al., 1986), whose cells are known to
strongly express IL-2R (Korsmeyer et al., 1983). In a
previous report we demonstrated a strong cytoplasmic
positivity for IL-2R in H and RS cells (Pizzolo et al., 1984).
In addition, activated lymphocytes expressing surface IL-2R
have also been found in tissues involved by HD in higher
proportion than in normal or reactive lymph nodes (Pizzolo
et al., 1984). All these considerations taken together, we
investigated the presence of sIL-2R in the serum of patients
with HD.
The study was performed on the serum of 23 patients with
HD during the active phase of their disease (20 at diagnosis
and 3 during the relapse). The stage of the disease, as
defined according to the Ann Arbor classification, was
assessed using standard procedures. The clinical findings of
our patients are summarized in Table I. Patient and control
sera, obtained from venous blood samples, were stored
frozen until use. The levels of sIL-2R were measured with a
commercial sandwich ELISA test kit (from T Cell Science,
Cambridge, MA, USA), developed using two monoclonal
antibodies directed against non-overlapping epitopes on the
human IL-2R.
The mean sIL-2R values, obtained from 20 age-matched
healthy individuals, were 248 + 124Uml-1. In 19/23 patients
sIL-2R levels were higher than normal controls, the highest
values being found in patients with constitutional symptoms
(stage B) or relapsed (mean value: stage A =815+628 Uml-1;
stage B+relapsed = 1,872+ 1,271 Uml -1; P <0.05) (Table I).
All patients with normal values belonged to stage A group.
Our data indicate that the majority of patients with HD in
active phase have increased values of sIL-2R in their serum,
which correlate with the severity of the disease, as suggested
by statistically significant higher values in stage B as
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Table I Soluble IL-2 receptor levels in the serum of patients with
Hodgkin's disease
Patients Sex Age Histology Clinical stage sIL-2R Uml-
STAGE A
1 F 21 NS II bulky 862
2 F 27 LP I 325
3 M 34 NS III 376
4 F 52 MC I 245
5 M 69 NS IV 771
6 F 18 NS II bulky 2,300
7 M 27 NS III 757
8 F 18 MC III 1,376
9 M 52 NS I 304
10 F 42 NS IV 830
mean +s.d.=815+628
STAGE B
11 F 20 NS III bulky 1,534
12 F 33 NS II 478
13 M 66 MC IV bulky 2,192
14 M 39 NS III 1,340
15 F 30 LP III 631
16 M 40 MC II 2,800
17 F 20 NS II 881
18 F 31 NS II bulky 4,800
19 M 59 MC IV 1,487
20 M 75 LD III 3,850
21a M 42 NS II bulky 960
22a M 62 NS II 1,850
23a M 22 MC IV 1,540
mean +s.d.=1,872+1,271
Mean values of sIL-2R+s.d. in the serum of 20 healthy controls:
248+124Uml-'.
aRelapsed patients.
LP=Iymphocyte predominance: NS =nodular sclerosis; MC=
mixed cellularity; LD=lymphocyte depletion.
Stage A and B: absence and presence of constitutional symptoms,
respectively.
Bulky =presence of bulky disease.
compared to A. A statement on the possible correlation with
other clinical characteristics, such as extension of the disease
(stages I to IV), histological subtype, and presence of a
bulky disease, can not be presently made due to the
relatively small series of patients. Further observations and
longitudinal studies will determine the value of our findings
as a prognostic factor and as a biological tool for moni-
toring disease status and possibly the effect of therapy. In
addition, the evidence herein provided of increased levels of
sIL-2R seems relevant to an understanding of some bio-
logical aspects of the disease. In fact, the excess of sIL-2R
released in vivo by chronically overstimulated cells might
remove the available IL-2 and block the IL-2/IL-2R modu-
lation necessary for a large number of biological responses.
As a consequence, some IL-2 dependent phenomena (Farrar
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et al., 1982; Smith & Cantrell, 1985) would be affected,
including T-cell proliferation, cutaneous delayed type hyper-
sensitivity, and regulation of NK activity. Indeed, most of
these functions are impaired in HD (Frydecka, 1985;
Romagnani et al., 1985). An indirect support to this view
comes from HCL, where the depressed NK in vitro activity,
concomitant with high serum levels of sIL-2R, can be
restored by the addition of exogenous IL-2 (Hooper et al.,
1986; Chilosi et al., submitted). Also in line with the above
considerations, evidence has been provided in HD of a
serum factor which can inhibit the phytohaemagglutinin-
induced transformation of normal lymphocytes (Scheurlen et
al., 1971). This factor is likely to correspond to the sIL-2R.
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